Equities analysts expect that Dynavax Technologies Corporation (NASDAQ:DVAX) will post earnings per share of $0.30 for the current quarter, according to Zacks. Two analysts have made estimates for Dynavax Technologies’ earnings. The highest EPS estimate is $0.95 and the lowest is ($0.35). Dynavax Technologies reported earnings per share of ($0.56) during the same quarter last year, which would indicate a positive year over year growth rate of 153.6%. The business is expected to announce its next quarterly earnings results on Monday, March 12th.

According to Zacks, analysts expect that Dynavax Technologies will report full year earnings of ($1.36) per share for the current financial year, with EPS estimates ranging from ($1.75) to ($0.25). For the next financial year, analysts expect that the firm will post earnings of ($1.19) per share, with EPS estimates ranging from ($1.65) to ($0.59). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Dynavax Technologies.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.15. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The firm had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.28 million. During the same quarter last year, the business posted ($0.90) EPS. Dynavax Technologies’s revenue was down 68.8% on a year-over-year basis.

Several equities research analysts recently weighed in on DVAX shares. ValuEngine lowered Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Friday. Cantor Fitzgerald boosted their price objective on Dynavax Technologies from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Thursday, November 9th. Cowen reiterated a “buy” rating and issued a $30.00 price target on shares of Dynavax Technologies in a research report on Friday, November 3rd. Royal Bank Of Canada reiterated an “outperform” rating and issued a $28.00 price target (up from $26.00) on shares of Dynavax Technologies in a research report on Monday, September 25th. Finally, William Blair reaffirmed an “outperform” rating and set a $30.00 price target on shares of Dynavax Technologies in a research note on Wednesday, August 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $25.17.

Several institutional investors and hedge funds have recently modified their holdings of DVAX. Swiss National Bank grew its position in Dynavax Technologies by 25.5% during the 2nd quarter. Swiss National Bank now owns 70,978 shares of the biopharmaceutical company’s stock worth $685,000 after acquiring an additional 14,400 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Dynavax Technologies by 24.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 155,095 shares of the biopharmaceutical company’s stock worth $1,496,000 after buying an additional 30,036 shares during the period. Patriot Financial Group Insurance Agency LLC lifted its stake in shares of Dynavax Technologies by 50.0% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 18,000 shares of the biopharmaceutical company’s stock valued at $419,000 after purchasing an additional 6,000 shares during the period. New York State Common Retirement Fund lifted its stake in shares of Dynavax Technologies by 29.4% in the 2nd quarter. New York State Common Retirement Fund now owns 52,400 shares of the biopharmaceutical company’s stock valued at $506,000 after purchasing an additional 11,899 shares during the period. Finally, Lord Abbett & CO. LLC acquired a new position in shares of Dynavax Technologies in the 2nd quarter valued at about $7,777,000. Institutional investors own 70.61% of the company’s stock.

Shares of Dynavax Technologies (NASDAQ DVAX) opened at $18.40 on Friday. Dynavax Technologies has a 1-year low of $3.70 and a 1-year high of $24.45.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/03/zacks-analysts-expect-dynavax-technologies-corporation-dvax-will-post-earnings-of-0-30-per-share.html.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.